Investor Resources
Annual Report & Accounts
General meeting documents
Results Presentations
- Interim Results for the Period Ending 30 June 2023 – presentation slides
- Interim Results for the Period Ending 30 June 2023
- Preliminary Results for the year ended 31 December 2022 – Presentation video
- Preliminary Results for the year ended 31 December 2022 – Presentation
- Preliminary Results for the year ended 31 December 2022
- Interim Results for the Period Ended 30 June 2022
- Preliminary Results for the year ending 31 December 2021 – Presentation slides
- Preliminary Results for the year ending 31 December 2021 – Presentation video
- Preliminary Results for the year ending 31 December 2021
- Interim Results for the 6 Months Period Ending 30th June 2021 – Presentation video
- Interim Results for the 6 Months Period Ending 30th June 2021 – Presentation slides
- Interim Results for the Period Ended 30 June 2021 and Business Update
- Business Update presentation 21 June 2021
- See more Results Presentations
Other Company Presentations and Videos
- AACR-NCI-EORTC conference – Poster teach in by Alastair Smith
- Dr. Fiona McLaughlin BIO 2023 presentation
- Coris Bioconcept acquisition and Dx strategy update – Alastair Smith video
- AACR AVA3996 poster / AVA6000 clinical data review – Alastair Smith video
- Vox interview – Fifth Cohort AVA6000 Phase Ia Dose Escalation
- Therapeutics Science Day 2023 – presentations
- Therapeutics Science Day 2023 – video recording
- 2022 AGM business update
- AVA6000 AACR 2022 poster presentation for investors – Alastair Smith
- Vox interview – Alastair Smith & Fiona McLaughlin – Feb 2022
- FAP-Activated Drugs and Drug-Conjugates: Immunotherapy World Congress 2021
- preCISION / AVA6000 explained – CEO video presentation
- Business Update webinar – June 2021
- Video Q and A with Alastair Smith on licensing and partnering opportunities (March 2021)
- Alastair Smith presents in Virtual Biotech Forum webinar
- Alastair Smith provides overview of pre|CISION™ prodrug technology and update on AVA6000 clinical trial
- Alastair Smith provides update on AffyXell collaboration and licence agreement
- Alastair Smith provides update on TMAC programme